Get started
Author

Maria Musisi

Early Weaning of HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis: Findings from Two Perinatal HIV Prevention Trials in Kampala, Uganda
2009 · Carolyne Onyango-Makumbi, Danstan Bagenda, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 75
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 34
PDF
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 23
PDF
A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, “the Nevirapine Repeat Pregnancy study”
2015 · Flavia M Kiweewa, Paul M Bakaki, et al. · BMC Public Health · 15
PDF
The Costs Associated With Adverse Event Procedures for an International HIV Clinical Trial Determined by Activity-Based Costing
2007 · Victoria B Chou, Saad B Omer, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 14
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 12
PDF
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial
2026 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 3
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial
2025 · Lisanne A.H. Bevers, Gabriela Toledo, et al. · EBioMedicine · 3
Works count: 8
Citation count: 179
H-index: 6
I10-index: 6
Year
Topic
Type